

PUBLIC SUMMARY DOCUMENT

Product: Review of Adhesive Remover Wipes in Subgroup 9(d)

Date of SPAP Meeting: 11 April 2016

1. Background

In March 2015 the Stoma Product Assessment Panel (SPAP) received an application from Hollister for a direct replacement of the Hollister Universal Wipes with Hollister Adapt Universal Wipes (SAS code 3554C), a non-sting alternative. No price premium was requested for the non-sting feature of the replacement wipes. As part of its consideration of this application, the SPAP therefore recommended that the unit price of \$0.32 be taken as the new benchmark price for protective wipes in this subgroup and that the prices of other listed non-sting wipes be reduced.

All suppliers who had remover wipes listed were contacted in April 2015 and advised of the SPAP recommendations that the unit price of products would be reduced. They were advised that Government approval would be sought to reduce the price of their products unless they provided justification for a price premium by 31 January 2016.

2. Applications

Applications were received from suppliers as shown in the table below.

Supplier	Product	SAS Code	Unit Price	Monthly Max.
Coloplast	Brava No Sting Adhesive Remover Wipes	3903K	\$0.398	60
Omnigon	Welland Adhesive Remover Wipes	9882D	\$0.478	50
ConvaTec	Niltac Adhesive Remover Wipes	80006W	\$0.398	30

3. SPAP Comment

The SPAP agreed that the Hollister Adapt Universal Wipe is an adequate product to remove adhesive from the peristomal skin and that it is a suitable comparator for the other products being reviewed.

The Panel considered the evidence provided to support the claims of superiority made by the applicants. It acknowledged that different products comprised different compositions, for example, that some were silicon based and some water based. The Panel decided that these differences would not be taken into consideration because the evidence provided failed to support that one formulation works better than another. The Panel agreed that the non-sting nature of the products was of primary importance.

The SPAP agreed that no clinical evidence had been provided to prevent the Hollister Adapt Universal Wipes from becoming the benchmark product for remover wipes in subgroup 9(d). The SPAP recommended that the unit price per wipe of \$0.32 be taken as the new benchmark price for adhesive remover wipes in this subgroup.

The Panel agreed that the evidence presented did not support superiority to justify an increased price by any applicant.

The SPAP noted that the monthly maximum quantities varied between the wipes listed in subgroup 9(d) and agreed that a consistent quantity should be applied. It was determined that a quantity of 60 was appropriate.

It was also noted that three suppliers had accepted the price reduction and two suppliers did not provide evidence. The Panel further noted that the remaining suppliers who wished to retain their current price did not provide sufficient clinical evidence to justify an increased price.

4. SPAP Recommendation

The SPAP recommended that all remover wipes in subgroup 9(d) have the unit price reduced to \$0.32 and the maximum monthly quantity amended to 60 per month.

This recommendation will result in changes to the following listed products:

Supplier	Product	SAS Code	Amendment
Ainscorp	Salts Wipe Away adhesive remover wipes	9854P	Unit price and maximum monthly quantity
Coloplast	Brava no-sting adhesive remover wipes	3903K	Unit price
ConvaTec	Niltac adhesive remover wipes	80006W	Unit price
ConvaTec	ConvaCare adhesive remover wipes	3522J	Maximum monthly quantity
Omnigon	Welland no-sting adhesive remover wipes	9882D	Unit price and maximum monthly quantity
Omnigon	Eakin Release Wipes	3786G	Unit price
Smith & Nephew	Adhesive remover wipes	3542K	Maximum monthly quantity
Hollister	Adapt Universal remover wipes no sting	3554C	Maximum monthly quantity

The SPAP confirmed that the price of \$0.32 and monthly maximum quantity of 60 units would be the benchmark for any future listings in subgroup 9(d).

5. Context for Decision

The SPAP helps decide whether stoma products should be subsidised and, if so, the conditions of their subsidisation in Australia. It considers submissions in this context. An SPAP decision not to recommend listing or changes to a listing does not represent a final SPAP view about the merits of a particular stoma product. A company can resubmit to the SPAP following a decision not to recommend listing or changes to a listing. The SPAP is an advisory committee and as such its recommendations are non-binding on Government. All SPAP recommendations are subject to Cabinet/Ministerial approval.